Minimally invasive laser-assisted lipolysis system receives FDA clearance

May 2, 2008, Yokneam, Israel--Syneron Medical has introduced the LipoLite, a new device for laser-assisted lipolysis, following U.S. Food and Drug Administration (FDA) clearance for laser-assisted lipolysis and additional dermatological procedures.

May 2, 2008, Yokneam, Israel--Syneron Medical has introduced the LipoLite, a new device for laser-assisted lipolysis, following U.S. Food and Drug Administration (FDA) clearance of the device for laser-assisted lipolysis and additional dermatological procedures.

According to the company, LipoLite is both a minimally invasive alternative and a complement to traditional liposuction fat-removing procedures. The procedure requires only local anesthetic and is designed to provide patients lasting results with little downtime and a high level of safety. For physicians, the small, compact LipoLite system is comfortable to use, upgradable to support future applications, and fits easily on tabletops.

"LipoLite allows me to remove fat in body areas that were not possible with traditional liposuction," stated Dr. W. Tracy Hankins, a board certified plastic surgeon at Ariana Cosmetic Surgery & Laser Center in Las Vegas.

LipoLite features OptiPulse technology, which optimizes the mechanical breakdown of target tissue and the thermal destruction of fat cell membranes during procedures. OptiPulse utilizes two unique pulse energy levels and pulse repetition rates to provide physicians with precise control.

"During clinical trials, the treatment provided good results with minimal pain," said Dr. Stephen Mulholland, board-certified plastic surgeon and medical director of SpaMedica in Toronto. "For many of the trial participants, pairing LipoLite laser lipolysis with VelaShape™ follow up procedures was the ideal combination for a minimally invasive treatments leading to body shaping."

According to the American Society of Aesthetic Plastic Surgery, the number of liposuction procedures increased 158 percent from 1997 to 2007. With more than 450,000 procedures performed in 2007, liposuction was the most frequently performed surgical cosmetic procedure last year. Purchase of the LipoLite device provides a new revenue stream for physicians at an affordable price for those wishing to enter the growing market for minimally invasive body shaping treatments.

"The LipoLite device marks Syneron's entry into the lipolysis market and expansion of the company's offerings for doctors to provide their clients with body shaping treatments," said Doron Gerstel, CEO of Syneron. "We are confident that with the combination of Syneron's existing Vela product lineup and this new lipolysis device our physician partners will be able to offer a more well-rounded aesthetic service package to patients and we at Syneron will continue to provide our doctors with more options for success."

More in Biomedicine